We also proved, for the first time, that the metabolomic spectral patterns spotted by our MRSI-based surrogate biomarker of therapy response were also observed using anti-PD-1 monotherapy, in agreement with these changes being, at least partially, contributed by the local immune system action against tumour cells. Here, PDCD1 is linked to neoplasm.